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Abstract Real-time quantitative RT-PCR (RT-qPCR) is a
“gold” standard for measuring steady state mRNA levels
in RNA interference assays. The knockdown of the
epidermal growth factor receptor (EGFR) gene with
eight individual EGFR small interfering RNAs (siRNAs)
was estimated by RT-qPCR using three different RT-
qPCR primer sets. Our results indicate that accurate
measurement of siRNA efficacy by RT-qPCR requires
careful attention for the selection of the primers used to
amplify the target EGFR mRNA. We conclude that when
assessing siRNA efficacy with RT-qPCR, more than one
primer set targeting different regions of the mRNA
should be evaluated and at least one of these primer sets
should amplify a region encompassing the siRNA
recognition sequence.
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1 Introduction
RNA interference (RNAi) can mediate a short-term or
prolonged silencing of gene expression at the RNA and
protein level. Knockdown efficiency is typically measured
at the mRNA level by quantitative RT-PCR (RT-qPCR) or
estimated at the protein level by immunoblot, enzyme-
linked immunosorbent assay, or immunohistochemistry [1].
Many prefer measuring the relevant protein with immuno-
blot directly because protein knockdown is most relevant to
the observable phenotype under study. However, in
practice, a suitable antibody to a given target protein may
not always be readily available or will not allow a
quantitative estimate of the magnitude of the effect of
RNAi. The long turn over time of many proteins may
underestimate the RNAi effect at the mRNA level. A direct
measurement at the mRNA level is therefore often the
preferred method to more directly verify that RNAi is
effectively decreasing the amount of the transcript. Real-
time RT-qPCR is the “gold” standard for measuring steady-
state mRNA levels. Hence, an accurate measurement
method of the mRNA knockdown is needed. There are
indications that mRNAs are not completely degraded after
24 h of RNAi exposure [2]. Therefore, the location of the
primer might be relevant as some primer sets may amplify
remaining cleavage products, leading to an underestimation
of the RNAi efficacy [3]. Despite this, numerous publica-
tions on RNAi with RT-qPCR do not evaluate the primers
choice. The lack of precise criteria for choosing the target
sequence for RT-qPCR amplification is surprising. Here,
evidence is presented that the location of RT-qPCR primers
is critical in the evaluation of the epidermal growth factor
receptor (EGFR) small interfering RNA (siRNA) efficacy,
even up to 72 h post-treatment in lung cancer cells.
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2 Material and Methods
2.1 siRNA Transfection
Eight siRNAs targeting wild-type EGFR sequences were
analyzed (Table 1, Fig. 1a). EGFR siRNA604 and EGFR
siRNA1247 were from Invitrogen (Ref.SKU#12938-076,
EGFR validated stealth duo pack, Invitrogen, Merelbeke,
Belgium); the other siRNAs were synthesized by Euro-
gentec (Eurogentec S.A., Liege, Belgium). All the
sequences used for siRNAs were finally blasted (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) to avoid silencing unre-
lated genes. The glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) positive control siRNA was from
Invitrogen (ref. SKU#12935-140 Stealth RNAi GAPDH
Positive Control, Invitrogen Merelbeke, Belgium). Euro-
gentec provided the negative control siRNA (OR-0030-
neg 05, Eurogentec S.A., Liege, Belgium), a proprietary
siRNA sequence that does not correspond to any human
gene. TOX Transfection Control and siGLO Green
Transfection Indicators were ordered from Thermo Scien-
tific Dharmacon (ref. D-001630-01-02; D-001500-01-05,
Thermo Scientific Dharmacon, Blenheim, England). The
human non-small cell lung cancer cell line NCI-H358,
wild type for EGFR, was obtained from the American
Type Culture Collection (Netherlands) and cultured in
RPMI 1640 medium (Invitrogen Corp., Gent, Belgium),
supplemented with 10% heat-inactivated fetal bovine
serum (Perbio Science NV, Erembodegem, Belgium),
2 mM L-glutamine and 1 mM sodium pyruvate at 37°C
in a humidified incubator with 5% CO2 but without
penicillin or streptomycin, which will otherwise cause cell
death during lipofectamine transfection. Cell line H358
was transfected with EGFR siRNAs, a negative control
siRNA or positive GAPDH control siRNA at 40 nM using
1.5 μl Lipofectamine 2000 (Invitrogen Merelbeke, Belgium)
per well in a 24-well format in triplicate.
2.2 RNA Extraction and LightCycler Real Time PCR
The EGFR mRNA level was determined 48 and 72 h post-
transfection by RT-qPCR. Total cellular RNA isolation was
performed on the ABI PRISM 6100 prepstation using the
AbsoluteRNA Solution (Applied Biosystems, Lennik,
Belgium) to remove contaminating DNA and PCR inhib-
itory substances. RNA concentrations were determined
using a ND-1000 NanoDrop (Thermo Fisher Scientific,
Wilmington, DE, USA), and used for normalization of the
input RNA in the RT-qPCR. Two hundred nanogram of
cellular RNA was converted to cDNA with a specific
reverse primer (sequences see Table 2) using Moloney
murine leukemia virus reverse transcriptase (RT-RTCK-03,







































































































































































































































































































































































































































































































































































































































































































































10 μl. The reverse transcription step was performed on an
Applied Biosystems Thermocycler at 25°C for 10 min for
the initial step, 30 min at 48°C for the reverse transcription
step and 95°C for 5 min to inactivate the reverse
transcription enzyme. Oligonucleotide primers (purchased
from Eurogentec S.A., Liege, Belgium) for EGFR were
based upon GenBank sequence (ENSEMBL sequence:
ENST00000275493, identical to NM_005228.3) and for
GAPDH, Ensembl sequence: ENSG00000111640, identical
to NM_002046.3. The primers were designed using the
Roche LightCycler Probe Design Software v1.0 (Idaho
Technology, Salt Lake City, UT, USA), FastPCR (Version
5.4 for Windows), followed by BLAST analysis (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Several transcript-specific
primer sets were designed to be located in different exons
or spanning an exon–exon border to avoid amplification of
genomic DNA (Table 2). RT-qPCR analysis was carried out
on a LightCycler 1.5 using the Faststart DNA master SYBR
green mastermix, and with three different primer sets
(Table 2, Fig. 1a). The quality of the amplified fragments
was monitored using melting curve analysis and agarose gel
electrophoresis. Quantitative values were obtained from the
PCR quantification cycle number (Cq) at which point the
increase in signal for the PCR product was exponential. The
target mRNA abundance in each sample was normalized to
its GAPDH mRNA level as ΔCq=CqEGFR−CqGAPDH. The
value ΔΔCq was defined as the difference with a mock-
transfected control. Experiments were performed in triplicate.
The knock-down ratio of EGFR RNA expression was
calculated with the formula: (1−1/2ΔΔCq)×100% [4].
2.3 Protein, Viability, and Apoptosis Experiments
Protein downregulation was analyzed by Western blot with
a primary antibody against EGFR (1:1,000 dilution, Anti-
EGFR, non-phospho-Tyr1173, clone 20 G3, Millipore
Fig. 1 Determination of EGFR siRNA knockdown efficiency in
H358 cells with RT-qPCR. a Schematic diagram of the EGFR gene
exon (boxes) structure and location of siRNAs and RT-qPCR primer
sets. For the siRNAs sequences, see Table 1. For the primers
sequences, see Table 2. Primer sets were named according to the
order of the sequences. b EGFR mRNA knockdown efficiency
detected by RT-qPCR amplification from EGFR siRNA-treated
H358 cells using either the primer set q1,q2 and q3 at 48 h (left),
and at 72 h (right). Transfections were performed in triplicate
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mouse monoclonal IgG1К, Catalog # 05-484, Lot # 30267,
Bio-connect, Huissen, The Netherlands.). The inhibition
ratio of EGFR protein expression was calculated with the
following formula: inhibition ratio of EGFR protein
expression=(1—the relative intensity of EGFR expression
in the siRNA experiment group/the relative intensity of
EGFR in the mock control group)×100%. Cell viability
was determined with the CellTiter-Blue® Cell Viability
Assay (G8080, Promega, Madison, USA). The calculation
of results was as: fluorescence of siRNA/mock control×
100%. Caspase-3/7 activity was measured by Apo-ONE®
Homogeneous Caspase-3/7 Assay (G7790, Promega,Madison,
USA). Caspase-3/7 activity was measured by fluorescence:
assay siRNA/mock control×100%. The effects of EGFR
siRNAs on apoptosis and nuclear morphology in the cells were
assessed by Hoechst 33342 (Sigma-Aldrich N.V. Bornem,
Belgium) and propidium iodide (Sigma-Aldrich N.V. Bornem,
Belgium) double fluorescent chromatin staining. Viable,
apoptotic, and necrotic cells were counted in ten different fields
under a ×200 magnification in each well in three independent
experiments by two persons, and the average result was
compared to the mock control. Values were presented as the
mean ± standard deviation.
3 Results and Discussion
In the present study, we evaluated the RT-qPCR assay used to
measure the siRNA knockdown of EGFR expression. In our
experiments, we were interested in determining the ability of a
series of EGFR siRNAs to knock down the levels of
endogenous EGFRmRNA expression in a human lung cancer
cell line expressing wild-type EGFR. To exclude effects of
transfection efficiency on siRNA efficacy, we determined
H358 cells transfection efficiency with two approaches: cell
fluorescence by siGLO transfection indicators and cell death
induced by TOX transfection control. The transfection
efficiency was higher than 81% at 48 h and 92% at 72 h, as
accessed by either CellTiter-Blue® Cell Viability Assay, or
fluorescence, as accessed by fluorescence microscopy (data
not shown). These data suggested that the transfection
efficiency was nearly optimal with all siRNAs tested. Of the
eight siRNAs examined, s604, s752, and s1247 siRNAs
showed the highest efficiency in the knockdown of the EGFR
mRNA (Fig. 1b). With primer sets q1 and q3 initially used,
the reduction of EGFR transcript levels was not greater than
57% at 48 h. We then redesigned a primer set q2 to overlap
or encompass the EGFR target site of siRNA s1247. Upon
reexamination with primer set q2, which encompasses the
target site and using siRNA s1247, a 71% decrease of the
EGFR mRNA level was observed. It was the strongest effect
observed for all eight siRNAs tested. In contrast, the primer





















































































































































































































































































































































































































































































































































































































s604 and s752 experiments in comparison to what was
measured with primer set q1 for the same siRNAs. This
primer set q1 amplifies a sequence that locates nearer to the
target sequence of s604 and s752. Similar results were
observed at 72 h: with primer set q2, a knockdown of 72%
was found in the s1247 experiments, whereas with the same
siRNA q1 detected a 53% knockdown and q3 a 53%
knockdown (Fig. 1b).
RT-qPCR amplification of a specific targeted mRNA
sequence reflects the integrity of that fragment, but does not
necessarily represent an intact mRNA. Our data suggest
that the EGFR mRNA fragments amplified by the q1 or q3
Fig. 2 Down-regulation of EGFR protein levels and phenotypic
consequences of EGFR knockdown. a Western blot was performed to
determine the down-regulation levels of EGFR protein. b Cell viability
was detected by CellTiter-Blue® Cell Viability Assay. c Caspase-3/7
activity was measured by Apo-ONE® Homogeneous Caspase-3/7
Assay. d, e Viable and apoptotic cells were counted with Hoechst
33342 and propidium iodide (PI) double fluorescent chromatin staining.
The aggregate results are consistent with the mRNA knock down results
obtained in the RT-qPCR experiments and confirm that of the siRNAs
tested, the s1247 is the most powerful siRNA on H358 cells to down-
regulate the EGFR protein level, inhibit the cell viability and induce
apoptosis in comparison to other siRNAs (results see Table 1)
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primer sets after transfection of s1247 remain more intact
despite RNA cleavage and thus result in an overestimation of
the amount of remaining intact target mRNA. The relatively
higher knockdown read-out with primer set q1, after transfec-
tion with s604 and s752, compared to q3, is also consistent with
this observation (Fig. 1b). These results thus suggest that
s1247 is the most effective of the siRNA’s tested.
To further corroborate this hypothesis, we analyzed
EGFR protein levels with Western blot and studied possible
phenotypic consequences of EGFR down-regulation in
H358 cells. Cell viability and caspase-3/7 activity were
measured and, in addition, we evaluated the induction of
apoptosis. The aggregate results of these experiments are
consistent with the mRNA knock down results obtained in
Fig. 2 (continued)
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the RT-qPCR experiments and confirm that of the siRNAs
tested, the s1247 is the most powerful siRNA on H358 cells
to down-regulate the EGFR protein level, inhibit the cell
viability and induce apoptosis in comparison to other
siRNAs (Table 1, Fig. 2).
To verify whether the effect of primer set choice on RT-
qPCR results is also observed with other messengers, we
transfected a positive, validated GADPH siRNA (Invitrogen,
sequence unknown) into H358 cells and measured the
GAPDH mRNA knockdown level with three different primer
sets locating in different positions. The data showed that with
different locations, the primers detected different knockdown
efficiencies (data not shown), and the best primer set was
GAPDH 820 F and 1106R (Table 2). The results from
GAPDH RNAi are analogous to the data obtained with the
EGFR mRNA suggesting that these findings can be
generalized, i.e., measurements of the knockdown efficiency
can be influenced by the primer set used for RT-qPCR.
SiRNA induced cleavage of mRNA appears to be followed
by degradation of the messenger, which is assumed to be
complete 24–48 h after siRNA treatment [5]. Consequently
the position of the PCR primers within the mRNA (cDNA)
is generally considered irrelevant, and many publications do
not provide a rationale for the primers chosen and
specifically do not include qPCR primers that overlap with
the siRNA target sequence. However, there are indications
that mRNAs are incompletely degraded 24 h after transfec-
tion as evidenced by others in a Northern blot analysis
following treatment with siRNAs against coagulation factor
III [2]. Our results corroborate and strengthen observations
made by Shepard et al. [3]. In a study targeting the
connective tissue growth factor in human trabecular mesh-
work cells, they found that the location of the qPCR primers
relative to the siRNA target sequence profoundly influenced
the RT-qPCR results, by as much as 60%, 24 h post-
transfection. They also showed that these results were
independent of siRNA concentration, siRNA/lipid ratio, or
transfection efficiency. Primer sets that did not overlap the
siRNA target sequence yielded a lower knockdown efficien-
cy, which can be explained by the existence of partially
degraded mRNA molecules that are still detected in the RT-
qPCR assay. However, these results favoring a primer
position effect were based upon analysis 24 h post-
treatment, a time point at which abundant mRNA may have
been cleaved by the argonaute protein, but not yet degraded
by exonucleases. More recently, the importance of primer
position for assessment of MYCN oncogene siRNA silenc-
ing in a human neuroblastoma cell line (IMR-32) was also
described by the group of Vandesompele [6]. Their RT-
qPCR analysis was at 48 h post-transfection. Our present
results strongly suggest that amplification of incomplete-
ly degraded mRNA molecules, as observed with the
EGFR q1 and q3 primer sets with siRNA s1247, may
lead to underestimation of the siRNA efficacy, at least up
to 72 h post-treatment. Nevertheless, the fact that these
position effects were measureable in different cell types
(trabecular cells, neuroblastoma, and lung cancer cell
lines), and with different genes (connective tissue growth
factor, MYCN oncogene, EGFR, GAPDH), strongly
suggests that incomplete degradation of mRNA following
siRNA treatment is a general phenomenon that may
significantly affect RT-qPCR results in RNAi research.
4 Summary
We thus conclude that there is an unexpected but significant
interdependence between the EGFR-targeting siRNA
sequence and the RT-qPCR amplification region for assessing
the efficacy of the siRNA target gene knockdown and that this
finding can be extended to other mRNAs in lung cancer cells.
We therefore recommend that qPCR primers for siRNAwork
should span the putative siRNA cleavage site, thus avoiding
the amplification ofmRNAmolecules that underwent only the
initial steps of the siRNA induced degradation process. It is
also recommendable to test more than one primer set at
different locations on the mRNA, particularly for mRNA
targets that appear to be refractory to siRNA-mediated
cleavage. Ideally, at least one of the primer sets should
amplify a region encompassing the siRNA recognition
sequence to ensure optimum siRNA efficacy readout.
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